linco-spectin antibiotic soluble powder for poultry and swine
zoetis australia pty ltd - lincomycin as lincomycin hydrochloride; spectinomycin as spectinomycin sulfate tetrahydrate - oral powder, pre-mix - lincomycin as lincomycin hydrochloride antibiotic active 222.0 mg/g; spectinomycin as spectinomycin sulfate tetrahydrate antibiotic active 445.0 mg/g - antibiotic & related - pigs | poultry | boar | breeders | broiler | chickens | chicks | chooks | day old chicks | gilt | hatchlings | layers | piglet | - antibiotics - oral, parenteral | bacterial enteritis | chronic respiratory disease | infections of the respiratory tract | mycoplasma spp. | swine dysentery | acute respiratory infections | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | bronchiseptica | bronchitis | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | infected wounds | infections | lactating | mastitis | pharyngitis | pneumonia | post-weaning bacterial enterit | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection | tonsillitis
oxymav 100 soluble broadspectrum antibiotic powder
mavlab pty. ltd. - oxytetracycline - oral powder, pre-mix - oxytetracycline antibiotic active 93.0 g/kg - antibiotic & related - calf | pigs | poultry broilers (meat for human consum) | poultry layers (eggs for human consump) | beef calf | boar | bovine | c - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds
rilexine 75 cephalexin antibiotic tablets for dogs and cats
virbac (australia) pty ltd - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 75.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - antibiotic - anti-infective | enterobacter spp. | escherichia coli (e. coli) | infections of soft cutaneous tissue | infections of the digestive tract | infections of the respiratory tract | infections of the urinary tracts | klebsiella spp. | osteomyelitis | proteus spp. | salmonella | shigella spp. | staphylococcus aureus | abrasions | abscesses | acute respiratory infections | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | bronchiseptica | bronchitis | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | escherichia coli | feed efficiency | fungal infections | girth galls | group d streptococcus | including b-lactamase producin | infections | inflammed pads | itching | keratolytic | klebsiella spp. | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pharyngit
ilium oxytet-200 l.a. long-acting broad-spectrum antibiotic injection
troy laboratories pty ltd - oxytetracycline - parenteral liquid/solution/suspension - oxytetracycline antibiotic active 200.0 mg/ml - antibiotic & related - cattle | pigs | sheep | beef | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ew - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds
neoject 200 antibiotic injection
ceva animal health pty ltd - neomycin sulfate - parenteral liquid/solution/suspension - neomycin sulfate antibiotic active 200.0 mg/ml - antibiotic & related - cat | cattle | dog | horse | pigs | sheep | beef | bitch | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | - antibiotics - oral, parenteral | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | infected wounds | infections | lactating | mastitis | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection
chloramphenicol 150 broad spectrum antibiotic
ceva animal health pty ltd - chloramphenicol - parenteral liquid/solution/suspension - chloramphenicol antibiotic active 150.0 mg/ml - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - antibiotics - oral, parenteral | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | infected wounds | infections | lactating | mastitis | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection
chlor-b 500 broad spectrum antibiotic plus vitamins
ceva animal health pty ltd - chloramphenicol; vitamin b3 = nicotinamide; vitamin b5 calcium salt = calcium pantothenate; vitamin b2 = riboflavin; vitamin b1 (thiamine hydrochloride); vitamin b6 (pyridoxine hydrochloride) - oral tablet - chloramphenicol antibiotic active 500.0 mg/tb; vitamin b3 = nicotinamide vitamin-b3 active 20.0 mg/tb; vitamin b5 calcium salt = calcium pantothenate vitamin-b5 active 10.0 mg/tb; vitamin b2 = riboflavin vitamin-b2 active 4.0 mg/tb; vitamin b1 (thiamine hydrochloride) vitamin-b1 active 10.0 mg/tb; vitamin b6 (pyridoxine hydrochloride) vitamin-b6 active 2.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - antibiotics - oral, parenteral | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | infected wounds | infections | lactating | mastitis | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection
d-gam human anti-d immunoglobulin
bio products laboratory limited - anti, d immunoglobulin, human - solution for injection - anti-d immunoglobulin, human 250 international unit(s)/millilitre - immune sera and immunoglobulins
qarziba (previously dinutuximab beta eusa and dinutuximab beta apeiron)
recordati netherlands b.v. - dinutuximab beta - neuroblastoma - antineoplastic agents - qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.in patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, qarziba should be combined with interleukin 2 (il 2).
feiba- anti-inhibitor coagulant complex kit
takeda pharmaceuticals america, inc. - anti-inhibitor coagulant complex (unii: cs849dun3m) (anti-inhibitor coagulant complex - unii:cs849dun3m) - anti-inhibitor coagulant complex 500 [usp'u] in 20 ml - feiba is an anti-inhibitor coagulant complex indicated for use in hemophilia a and b patients with inhibitors for: - control and prevention of bleeding episodes - perioperative management - routine prophylaxis to prevent or reduce the frequency of bleeding episodes. feiba is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor viii or coagulation factor ix. - known anaphylactic or severe hypersensitivity reactions to feiba or any of its components, including factors of the kinin generating system. - disseminated intravascular coagulation (dic). - acute thrombosis or embolism (including myocardial infarction). risk summary there are no data with feiba use in pregnant women to inform a drug-associated risk. there are no adequate and well-controlled studies in pregnant women. animal reproduction studies have not been conducted with feiba. it is also not known whether feiba can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. in the u.s. general population, the estimated background risk for major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. there is no information available on the effect of feiba on labor and delivery. risk summary there is no information regarding the presence of feiba in human milk, the effect on the breastfed child, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for feiba and any potential adverse effects on the breastfed child from feiba or from the underlying condition. safety and efficacy of feiba have been evaluated in nine pediatric subjects treated in the routine prophylaxis trial including 4 subjects ≥7 to <12 years of age and 5 subjects ≥12 to <16 years of age. the dosing for all pediatric subjects was based on body weight. a total of 576 infusions were given for the treatment of 223 bleeding episodes (504 infusions for joint bleeding episodes, 72 infusions for muscle and soft tissue bleeding episodes). in 223 (100%) of the episodes, hemostasis was achieved with one or more infusions. hemostatic efficacy was rated as excellent or good in a majority (96.9%) of the bleeding episodes in both regimens at 24 hours post infusion. the median annualized bleeding episode rate (abr) for children ≥7 to <12 years of age was 7.7 bleeds per patient per year, as compared to 39 for subjects treated with on-demand therapy [see clinical studies (14)] . the safety and efficacy of feiba has not been evaluated in neonates. the safety and efficacy of feiba has not been evaluated in subjects ≥65 years of age.